Endometrioziste Yeni Medikal Tedavi Yöntemleri

Uysal, Gulsum; Cingillioglu, Basak; AKSOY, Ülkü; KARAKILIÇ, Eda; çağlı, fulya; Açmaz, Gökhan; AKSOY, Hüseyin

Endometrioziste Yeni Medikal Tedavi Yöntemleri

Gülsüm UYSAL, (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Fulya ÇAĞLI, (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Hüseyin AKSOY, (Kayseri Asker Hastanesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Kayseri, Türkiye)

Ülkü AKSOY, (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Başak CINGILLIOĞLU, (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Eda KARAKILIÇ, (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Gökhan AÇMAZ (Kayseri Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Kayseri, Türkiye)

Kafkas Tıp Bilimleri Dergisi

23 0

Yıl: 2015 Cilt: 5 Sayı: 3 Sayfa Aralığı: 109 - 119 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Endometrioziste Yeni Medikal Tedavi Yöntemleri

Öz:

Endometriozis üreme çağındaki kadınların %6-10'unu etkileyen infertilite ve pelvik ağrıya neden olan yaygın görülen jinekolojik bir durumdur. İnfertil kadınların %20-50'sinde, kronik pelvik ağrısı olan kadınların ise %20-70'inde görülür. Endometriozis tedavisi her zaman klinik açıdan zor bir durum olmakla beraber tam şifa ile sonlanan bir tedavi seçeneği yoktur.Endometriosis tedavisi medikal ve cerrahi ya da her ikisinin beraber kullanımı şeklinde sınıflandırılabilir. Tedavide birçok farklı medikal ajanlar kullanılabilir. En sık kullanılan medikal ajanlar non-sterod antiinflamatuar ilaçlar, analjezikler, gestajen ve türevleri, kombine oral kontraseptifler ve son zamanlarda levonorgestrel içeren rahim içi araçlardır. Kullanımda olan birçok farmakolojik tedavi seçeneği olmasına rağmen, hiçbiri tam anlamıyla başarı sağlamamaktadır. Çeşitli yeni medikal tedavi ajanları klinik denemelerden geçmektedir. Bu derlemenin amacı endometriosis tedavisinde yeni medikal tedavi yöntemlerini tartışmaktır.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Novel Medical Treatment Modalities of Endometriosis

Öz:

Endometriosisis a very common gynecological condition causing infertility and pelvic pain affecting 6%-10% of women at their reproductive ages. The prevalence is 20%-50% and 20%-70% in infertile women and women with chronic pelvic pain, respectively. The treatment of endometriosisis is always challenging for healthcare professionals and there is no curative treatment option for endometriosis.The treatment options for endometriosis can be classified as medical, surgical or combinations of the two approaches. Different medical agents exist for treatment of endometriosis. The most commonly used of these medical agents are non-steroidal antiinflammatory drugs, analgesics, gestagens or their derivatives, combined oral contraceptive pills, and more recently the levonorgestrel intrauterine system. Although there are numerous treatment options, available pharmacological treatment options in endometriosis are not fully satisfactory. Numerous new medical treatment agents are currently being tested in clinical trials in different phases. The purpose of the present review is to discuss the new medical treatment modalities in endometriosis.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1.Zhao SZ, Wong JM, Davis MB et al. The cost of inpatient endometriosis treatment: an analysis based on the Healthcare Cost and Utilization Project Nationwide Inpatient Sample. Am J Manag Care 1998;4:1127-34.
2.Gao X, Outley J, Botteman M et al. Economic burden of endometriosis. Fertil Steril. 2006; 86:1561-72.
3.Juares M,Tomas L. Endometriosis risk factors, symptoms and management. NewYork: Nova 2013 Chap 3, p77-111.
4.Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98:511-9.
5. Augoulea A, Alexandrou A, Creatsa M et al. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Arch Gynecol Obstet 2012; 286:99-103.
6. Murphy AA, Palinski W, Rankin S et al. Evidence for oxidatively modified lipid-protein complexes in endometrium and endometriosis. Fertil Steril 1998; 69:1092-4.
7. Kyama CM, Mihalyi A, Simsa P et al. Role of cytokines in the endometrial-peritonealcross-talk and development of endometriosis. Front Biosci (Elite Ed) 2009;1:444-54.
8. Seli E, Berkkanoglu M, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 2003;30:41-61.
9. Hayes EC, Rock JA. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768-80.
10. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003;21:209-22.
11. Kappou D, Matalliotakis M, Matalliotakis I. Medical treatments for endometriosis. Minerva Ginecol 2010;62:415-32.
12. Surrey ES. Gonadotropin-releasing hormone agonist and addback ther-apy: what do the data show? Curr Opin Obstet Gynecol 2010;22:283-8.
13. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22:450-9.
14. Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007;21:1066-81.
15. Kettel LM, Murphy AA, Mortola JF et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7.
16. Kettel LM, Murphy AA, Morales AJ et al. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994; 9:116-20.
17. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8.
18. Wang XL, Cheng WJ, Dai HH et al. ERB-041, a selective ERbagonist, inhibits iNOS in LPS activated peritoneal macrophages of endometriosis via suppression of NF-kB. Mol Immunol 2009;46:2413-8.
19. Harris HA, Bruner-Tran KL, Zhang X et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20:936-41.
20. Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a ran-domized controlled trial. Obstet Gynecol 2008;111:88-96.
21. Tabibzadeh S. The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Mol Hum Reprod 1996;2:77-92.
22. Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-alpha in women with endometriosis. Fertil Steril 2002;78:727-32.
23. D' Hooghe TM, Cuneo S, Nugent N, et al. Recombinant human TNF binding protein-1 (r-h TBP-1) inhibits the development of endometriosis in baboons: a prospective randomized, placebo- and drug-controlled study. Fertil Steril 2001;76-81.
24. Balasch J, Creus M, Fabregues F, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 1997; 12: 2046-50.
25. Yildirim G, Attar R, Ficicioglu C, et al. Etanercept causes regression of endometriotic implants in a rat model. Arch Gynecol Obstet 2011;283:1297-302.
26. Islimye M, Kilic S, Zulfikaroglu E, et al. Regression of endometrial autografts in a rat model of endometriosis treated with etanercept. Eur J Obstet Gynecol Reprod Biol 2011; 159:184-9.
27. Barrier FB, Bates GW, Leland MM, et al. Efficacy of antitumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 2004;81:775-9.
28. Falconer H, Mwenda JM, Chai DC, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 2006;21: 1856-62.
29. Falconer H, Mwenda JM, Chai DC, et al. Effects of antiTNF-mAb treatment on pregnancy in baboons with induced endometriosis. Fertil Steril 2008;89: 1537-45.
30. González-Ramos R, Van Langendonckt A, Defrère S, et al. Involvement of the nuclear factor-?B pathway in the pathogenesis of endometriosis. Fertil Steril 2010; 94: 1985-94.
31. Zhang JJ, Xu ZM, Zhang CM, et al. Pyrrolidine dithiocarbamate inhibits nuclear factor-kB pathway activation and regulates adhesion, migration, invasion and apoptosis of endometriotic stromal cells. Mol Hum Reprod 2011;17:175-81.
32. Nasu K, NishidaM, Ueda T, et al. Application of the nuclear factor-kB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Phisiol Endocrinol Metab 2007;293:16-23.
33. Kim JH, Yang YI, Lee KT, et al. Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull 2011;34:580-5.
34. Piotrowski PC, Kwintkwiewicz J, Rzepczynska IJ, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod 2006;75:107-11.
35. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003;14:599-603.
36. Esfandiari N, Khazaei M, Ai J, et al.Effect of a statin on an in vitro model of endometriosis. Fertility and Sterility 2007 Feb; 87:257-62.
37. Vincent L, Chen W, Hong T, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001;495:159-66.
38. Nasu K, Yuge A, Tsuno A, et al. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells: a promising agent for the treatment of endometriosis. Fertil Steril 2009; 92:2097-9.
39. Sharma I, Dhawan V, Mahajan N,et al. In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil Steril 2010; 94:1639-46.
40. Yilmaz B, Ozat M, Kilic S, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online 2010;20:291-9.
41. Guney M, Oral B, Karahan N, et al. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril 2008;89: 934-42.
42. Yildirim G, Attar R, Ozkan F, et al. The effects of letrozole and melatonin on surgicallyinduced endometriosis in a rat model:a preliminary study. Fertility and Sterility 2010; 93: 1787-92.
43. Paul S, Sharma AV, Mahapatra PD, et al. Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis. J Pineal Res 2008;44:439-49.
44. Koc O, Gunduz B, Topcuoglu A, et al. Effects of pinealectomy and melatonin supplementation on endometrial explants in a rat model. Eur J Obstet Gynecol Reprod Biol 2010;153:72-6.
45. New L, Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 1998;8:220-228.
46. Zhou WD, Yang HM, Wang Q, et al. SB203580, a p38 mitogenactivated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. Hum Reprod 2010;25: 3110-6.
47. Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogenactivated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 2006;72:85-93.
48. Garzetti GG, Ciavattini A, Provinciali M, et al. Natural killer activity in stage III and IV endometriosis: impaired cytotoxicity and retained lymphokine responsiveness of natural killer cells. Gynecol Endocrinol. 1995; 9:125-30.
49. D'Hooghe TM, Hill JA. Endometriosis. In: Berek JS, ed. Novak's gynecology. 13th ed. Philadelphia: Lippincott Williams and Wilkins, 2002; p. 931-72.
50. Itoh H, Sashihara T, Hosono A, et al. Interleukin-12 inhibits development of ectopic endometriotic tissues in peritoneal cavity via activation of NK cells in a murine endometriosis model. Cytotechnology 2011;63:133-41.
51. Altintas D, Kokcu A, Kandemir B, et al. Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. Fertil Steril 2008;90:401-5.
52. Aytan H, Caglar P, Uygur D, et al. Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 2007;87:698-701.
53. Ocal G, Kokcu A, Cetinkaya MB, et al.Efficacy of levamisole on experimental endometriosis. Int J Gynaecology Obstet 2007;99:38-42.
54. Ceyhan S.T, Onguru O., Fidan U.et al. Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol 2011;154: 100-4.
55. Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011;179:880-9.
56. Osteen KG, Yeaman GR & Bruner-Tran K. Matrix metalloproteinases and endometriosis. Seminars in Reproductive Medicine 2003; 21: 155-163.
57. Mori T, Yamasaki S, Masui F, et al. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood) 2001;226:429-33.
58. Stilley JA, Birt JA, Nagel SC,et al.. Neutralizing TIMP1 restores fecundity in a rat model of endometriosis and treating control rats with TIMP1 causes anomalies in ovarian function and embryo development. Biol Reprod 2010;83:185-94.
59. Harada M. Cell Proliferation and apoptosis: detection of apoptosis in human endometriotic tissues. Mol Hum Reprod 1996; 2:307-15.
60. Meresman GF. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000;74:760-6.
61. Selam B. Extracellular matrix-dependent regulation of Fas ligand expression in human endometrial stromal cells. Biol Reprod 2002;66:1-5.
62. Lin Y-J. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 2006;147:1278-86.
63. Fauvet R. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours. Virchows Arch 2003;443:38-43.
64. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinasedependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004;25:2183-9.
65. Jana S, Paul S, Swarnakar S. Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway. Biochem Pharmacol 2012;83:797-804.
66. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002;955:89-100. 67. Donnez J, Smoes P, Gillerot S, et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998;13:1686- 90.
68. Taylor RN, Mueller MD. Anti-angiogenic treatment of endometriosis: biochemical aspects. Gynecol Obstet Invest 2004;57:54-6.
69. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun. 2007; 355:1-5.
70. Becker CM1, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84: 1144-55.
71. Whitworth A. Endostatin: are we waiting for Godot? J Natl Cancer Inst 2006; 98:731-3.
72. Veitonmäki N, Cao R, Wu LH, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 2004; 64:3679- 86.
73. Chen YH, Wu HL, Li C, et al. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 2006; 95:668-77.
74. Dabrosin C, Gyorffy S,Margetts P, et al. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002;161:909-18.
75. Hazzard TM, Rohan RM, Molskness TA, et al. Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine 2002;17:199-206.
76. Beerepoot LV, Witteveen EO, Groenewegen G, et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and longterm safety study. Clin Cancer Res 2003; 9:4025-33.
77. Nap AW, Dunselman GA, Griffioen AW et al. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005; 83:793-5.
78. Gómez R, Abad A, Delgado F, et al. A.Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril 2011;95:882-8.
79. Leitao VM, Moroni RM, Seko LM, et al.Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014;101:664-75.
80. Herbst RS, Madden TL, Tran HT, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002; 20:4440-7.
81. Laschke MW, Elitzsch A, Scheuer C,et al..Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006;149:137-44.
82. Laschke MW, Elitzsch A, Vollmar B,et al. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006; 21:262-8.
83. Pritts EA, Zhao D, Ricke E,et al. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002;87:1841-4.
84. Fan W, Yanase T, Morinaga H, et al. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. Endocrinology 2005;146:85-92.
85. Lebovic DI, Mwenda JM, Chai DC, et al. T.PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drugcontrolled study. Fertil Steril 2007;88:1108-19.
86. Moravek MB, Ward EA, Lebovic DI. Thiazolidinediones as therapy for endometriosis: a case series. Gynecol Obstet Invest. 2009;68:167-70.
87. Onalan G, Zeyneloglu HB, Bayraktar N. Fenofibrate causes regression of endometriotic implants: a rat model. Fertil Steril 2009;92:2100-2.
88. Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007; 92:3213-8.
89. Oner G, Ozcelik B, Ozgun MT, et al. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reprod 2010; 25:932-7.
90. Yilmaz B, Sucak A, Kilic S, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol 2010;202:368.
91. Foda AA, Aal I. Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profile. MEFSJ 2012;17: 262-7.
92. Dechaud H, Witz CA, Montoya-Rodriguez IA, et al. Mesothelial cell associated hyaluronic acid promotes adhesion of endometrial cells to mesothelium. Fertil Steril 2001; 76:1012-8.
93. Hasegawa A, Yoshino O, Osuga Y, et al. Hyaluronic acid reagent supressed endometriotic lesion formation in Mouse model. Fertil Steril 2010;93:2757-9.
94. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-96.
95. Mohammadzadeh A, Heidari M, Soltanghoraee H, et al. Evaluation of the effect of pentoxifylline on white blood cell count in serum and peritoneal fluid in female rats with endometriosis. J Obstet Gynaecol Res 2008;34:307-13.
96. Alborzi S, Ghotbi S, Parsanezhad ME, et al. Pentoxifylline therapy after laparoscopic surgery for diferent stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Minim Invasive Gynecol 2007; 14:54-8.
97. Szczepa?ska M, Ko?lik J, Skrzypczak J, et al. Oxidative stress may be a piece in the endometriosis puzzle. Fertil Steril. 2003; 79:1288-93.
98. Kavtaradze ND, Dominguez CE, Rock JA, et al. Vitamin E and C supplementation reduces endometriosis related pelvic pain. Fertil Steril 2003;161:189-95.
99. Pittaluga E, Costa G, Krasnowska E, et al. More than antioxidant: N-acetyl-L-cysteine in a murine model of endometriosis. Fertil Steril 2010;94:2905-8.
100. Wu Y, Guo SW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2008;137:198-203.
101. Imesch P, Fink D, Fedier A.Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril 2010;94:2838-42.
102. Richon VM, Sandhoff TW, Rifkind RA, et al.Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-9.
103. Liu M, Liu X, Zhang Y, et al. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci 2012; 19:360-73.
104. Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 2008; 89:246-50.
105. Chen Y, Chen C, Shi S, et al. .Endometriotic implants regress in rat models treated with puerarin by decreasing estradiol level. Reprod Sci. 2011; 18:886-91.
106. Laschke MW, Schwender C, Scheuer C, et al. Epigallocatechin 3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod. 2008;23:2308-18.
107. Xu H, Lui WT, Chu CY, et al. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod 2009; 24:608-18.

APA	Uysal G, çağlı f, AKSOY H, AKSOY Ü, Cingillioglu B, KARAKILIÇ E, Açmaz G (2015). Endometrioziste Yeni Medikal Tedavi Yöntemleri. , 109 - 119.
Chicago	Uysal Gulsum,çağlı fulya,AKSOY Hüseyin,AKSOY Ülkü,Cingillioglu Basak,KARAKILIÇ Eda,Açmaz Gökhan Endometrioziste Yeni Medikal Tedavi Yöntemleri. (2015): 109 - 119.
MLA	Uysal Gulsum,çağlı fulya,AKSOY Hüseyin,AKSOY Ülkü,Cingillioglu Basak,KARAKILIÇ Eda,Açmaz Gökhan Endometrioziste Yeni Medikal Tedavi Yöntemleri. , 2015, ss.109 - 119.
AMA	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G Endometrioziste Yeni Medikal Tedavi Yöntemleri. . 2015; 109 - 119.
Vancouver	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G Endometrioziste Yeni Medikal Tedavi Yöntemleri. . 2015; 109 - 119.
IEEE	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G "Endometrioziste Yeni Medikal Tedavi Yöntemleri." , ss.109 - 119, 2015.
ISNAD	Uysal, Gulsum vd. "Endometrioziste Yeni Medikal Tedavi Yöntemleri". (2015), 109-119.

APA	Uysal G, çağlı f, AKSOY H, AKSOY Ü, Cingillioglu B, KARAKILIÇ E, Açmaz G (2015). Endometrioziste Yeni Medikal Tedavi Yöntemleri. Kafkas Tıp Bilimleri Dergisi, 5(3), 109 - 119.
Chicago	Uysal Gulsum,çağlı fulya,AKSOY Hüseyin,AKSOY Ülkü,Cingillioglu Basak,KARAKILIÇ Eda,Açmaz Gökhan Endometrioziste Yeni Medikal Tedavi Yöntemleri. Kafkas Tıp Bilimleri Dergisi 5, no.3 (2015): 109 - 119.
MLA	Uysal Gulsum,çağlı fulya,AKSOY Hüseyin,AKSOY Ülkü,Cingillioglu Basak,KARAKILIÇ Eda,Açmaz Gökhan Endometrioziste Yeni Medikal Tedavi Yöntemleri. Kafkas Tıp Bilimleri Dergisi, vol.5, no.3, 2015, ss.109 - 119.
AMA	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G Endometrioziste Yeni Medikal Tedavi Yöntemleri. Kafkas Tıp Bilimleri Dergisi. 2015; 5(3): 109 - 119.
Vancouver	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G Endometrioziste Yeni Medikal Tedavi Yöntemleri. Kafkas Tıp Bilimleri Dergisi. 2015; 5(3): 109 - 119.
IEEE	Uysal G,çağlı f,AKSOY H,AKSOY Ü,Cingillioglu B,KARAKILIÇ E,Açmaz G "Endometrioziste Yeni Medikal Tedavi Yöntemleri." Kafkas Tıp Bilimleri Dergisi, 5, ss.109 - 119, 2015.
ISNAD	Uysal, Gulsum vd. "Endometrioziste Yeni Medikal Tedavi Yöntemleri". Kafkas Tıp Bilimleri Dergisi 5/3 (2015), 109-119.